{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:16:38Z","timestamp":1794352598100,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002556"],"award-info":[{"award-number":["82002556"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172651"],"award-info":[{"award-number":["82172651"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103293"],"award-info":[{"award-number":["82103293"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972768"],"award-info":[{"award-number":["81972768"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31930020"],"award-info":[{"award-number":["31930020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20201083"],"award-info":[{"award-number":["BK20201083"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["2108085MH287"],"award-info":[{"award-number":["2108085MH287"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["1908085QH332"],"award-info":[{"award-number":["1908085QH332"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Support Plan for Outstanding Young Talents of Anhui Education Department","award":["gxyq2021257"],"award-info":[{"award-number":["gxyq2021257"]}]},{"name":"the Key Research and Development Project of Anhui Province","award":["202104j07020019"],"award-info":[{"award-number":["202104j07020019"]}]},{"name":"the Talent Introduction Science Foundation of Yijishan Hospital, Wannan Medical College","award":["YR202110"],"award-info":[{"award-number":["YR202110"]}]},{"name":"the Talent Introduction Science Foundation of Yijishan Hospital, Wannan Medical College","award":["YR202109"],"award-info":[{"award-number":["YR202109"]}]},{"name":"the Funding of \"Peak\" Training Program for Scientific Research of Yijishan Hospital, Wannan Medical College","award":["GF2019J08"],"award-info":[{"award-number":["GF2019J08"]}]},{"name":"the Funding of \"Peak\" Training Program for Scientific Research of Yijishan Hospital, Wannan Medical College","award":["GF2019G17"],"award-info":[{"award-number":["GF2019G17"]}]},{"name":"the Science and Technology Project of Wuhu City","award":["2022jc52"],"award-info":[{"award-number":["2022jc52"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypoxia is a hallmark of cancer, and is closely intertwined with tumor immune evasion. Circular RNAs (circRNAs) have been implicated in tumor response to immune checkpoint blockades. However, hypoxia-associated circRNAs that orchestrate the association between hypoxia and response to immunotherapy remain poorly understood. Here, we aimed to determine the roles of hypoxia-associated circRNAs in immune escape of hepatocellular carcinoma (HCC) cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Differentially expressed hypoxia-associated circRNAs were determined using high-throughput sequencing technology. HCC patients treated with PD-1 blockade were enrolled to assess the clinical significance of circPRDM4. RT-qPCR, western blotting, flow cytometry, T cell-mediated tumor cell killing assay, and enzyme linked immunosorbent assay were used to investigate the roles of circPRDM4 in immune escape of HCC cells in vitro. Patient-derived xenograft mouse models and adoptive human tumor infiltrating lymphocyte-CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell transfer were adopted to evaluate the effects of circPRDM4 in vivo. RNA pull-down, mass spectrometry, RNA immunoprecipitation, chromatin immunoprecipitation, chromatin isolation by RNA purification, dual-luciferase reporter assays, dot blotting, DNA in situ hybridization, and immunoprecipitation were utilized to examine the interaction between circPRDM4, HIF-1\u03b1, and\n                      <jats:italic>CD274<\/jats:italic>\n                      promoter.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified circPRDM4 as a hypoxia-associated circRNA in HCC. circPRDM4 was upregulated in responders to PD-1 blockade and associated with therapeutic efficacy. In vitro and in vivo experiments showed that circPRDM4 induced PD-L1 expression and promoted CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell-mediated immune escape under hypoxic conditions. Mechanistically, circPRDM4 acted as a scaffold to recruit HIF-1\u03b1 onto\n                      <jats:italic>CD274<\/jats:italic>\n                      promoter, and cemented their interaction, ultimately promoting the HIF-1\u03b1-mediated transactivation of PD-L1.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These findings illustrated that circPRDM4 promoted immune escape of HCC cells by facilitating the recruitment of HIF-1\u03b1 onto the promoter of\n                      <jats:italic>CD274<\/jats:italic>\n                      under hypoxia, thereby inhibiting CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell infiltration in the tumor microenvironment. This work may provide a novel prognostic biomarker and therapeutic candidate for HCC immunotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-023-00378-2","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T08:04:20Z","timestamp":1675670660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["Hypoxia-associated circPRDM4 promotes immune escape via HIF-1\u03b1 regulation of PD-L1 in hepatocellular carcinoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Zhi-Qiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Liang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Zhou","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Dao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"1","key":"378_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"378_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"378_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","volume":"11","author":"Q Jia","year":"2022","unstructured":"Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11(1):24.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"378_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"378_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","volume":"73","author":"RC Sperandio","year":"2022","unstructured":"Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Hepatocellular carcinoma immunotherapy. Annu Rev Med. 2022;73(1):267\u201378.","journal-title":"Annu Rev Med"},{"issue":"1","key":"378_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21(1):28.","journal-title":"Mol Cancer"},{"issue":"3","key":"378_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38(3):193\u2013202.","journal-title":"J Clin Oncol"},{"issue":"1","key":"378_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390.","journal-title":"Lancet Oncol"},{"issue":"1","key":"378_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"key":"378_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev-med-060619-022830","volume":"73","author":"P Jayaprakash","year":"2022","unstructured":"Jayaprakash P, Vignali PDA, Delgoffe GM, Curran MA. Hypoxia reduction sensitizes refractory cancers to immunotherapy. Annu Rev Med. 2022;73:251\u201365.","journal-title":"Annu Rev Med"},{"issue":"1","key":"378_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 2021;40(1):24.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"378_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","volume":"74","author":"IB Barsoum","year":"2014","unstructured":"Barsoum IB, Smallwood CA, Siemens DR, Graham CH. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014;74(3):665\u201374.","journal-title":"Cancer Res"},{"issue":"5","key":"378_CR13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, et al. PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781\u201390.","journal-title":"J Exp Med"},{"issue":"1","key":"378_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41568-020-00306-0","volume":"21","author":"GJ Goodall","year":"2021","unstructured":"Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21(1):22\u201336.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"378_CR15","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s41571-021-00585-y","volume":"19","author":"LS Kristensen","year":"2021","unstructured":"Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2021;19(3):188\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"378_CR16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21(8):475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"378_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-021-01398-4","volume":"20","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang T, She Y, Wu K, Gu S, Li L, et al. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. Mol Cancer. 2021;20(1):105.","journal-title":"Mol Cancer"},{"issue":"19","key":"378_CR18","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1158\/0008-5472.CAN-20-4321","volume":"81","author":"J Ge","year":"2021","unstructured":"Ge J, Wang J, Xiong F, Jiang X, Zhu K, Wang Y, et al. Epstein-Barr virus-encoded circular RNA circBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1. Cancer Res. 2021;81(19):5074\u201388.","journal-title":"Cancer Res"},{"issue":"1","key":"378_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12943-021-01475-8","volume":"20","author":"DL Chen","year":"2021","unstructured":"Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer. 2021;20(1):166.","journal-title":"Mol Cancer"},{"issue":"7565","key":"378_CR20","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nature14883","volume":"524","author":"D Wu","year":"2015","unstructured":"Wu D, Potluri N, Lu J, Kim Y, Rastinejad F. Structural integration in hypoxia-inducible factors. Nature. 2015;524(7565):303\u20138.","journal-title":"Nature"},{"issue":"6","key":"378_CR21","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/hep.32062","volume":"74","author":"Q He","year":"2021","unstructured":"He Q, Liu M, Huang W, Chen X, Zhang B, Zhang T, et al. IL-1\u03b2-induced elevation of Solute Carrier Family 7 Member 11 promotes hepatocellular carcinoma metastasis through up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1. Hepatology. 2021;74(6):3174\u201393.","journal-title":"Hepatology"},{"key":"378_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00165-3","author":"F Liu","year":"2020","unstructured":"Liu F, Qin L, Liao Z, Song J, Yuan C, Liu Y, et al. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s40164-020-00165-3.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"378_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2021;19(3):151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"378_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.00018.2019","volume":"100","author":"C Riera-Domingo","year":"2020","unstructured":"Riera-Domingo C, Audig\u00e9 A, Granja S, Cheng WC, Ho PC, Baltazar F, et al. Immunity, hypoxia, and metabolism-the M\u00e9nage \u00e0 Trois of cancer: implications for immunotherapy. Physiol Rev. 2020;100(1):1\u2013102.","journal-title":"Physiol Rev"},{"issue":"1","key":"378_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","volume":"14","author":"XC Ding","year":"2021","unstructured":"Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, et al. The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia. J Hematol Oncol. 2021;14(1):92.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"378_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"issue":"1","key":"378_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"WY Zhou","year":"2020","unstructured":"Zhou WY, Cai ZR, Liu J, Wang DS, Ju HQ, Xu RH. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020;19(1):172.","journal-title":"Mol Cancer"},{"issue":"1","key":"378_CR28","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12943-021-01435-2","volume":"20","author":"Y Gu","year":"2021","unstructured":"Gu Y, Wang Y, He L, Zhang J, Zhu X, Liu N, et al. Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling. Mol Cancer. 2021;20(1):132.","journal-title":"Mol Cancer"},{"issue":"1","key":"378_CR29","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1038\/s41467-020-17944-5","volume":"11","author":"B Liu","year":"2020","unstructured":"Liu B, Ye B, Zhu X, Yang L, Li H, Liu N, et al. An inducible circular RNA circKcnt2 inhibits ILC3 activation to facilitate colitis resolution. Nat Commun. 2020;11(1):4076.","journal-title":"Nat Commun"},{"issue":"11","key":"378_CR30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41419-019-2028-9","volume":"10","author":"Y Feng","year":"2019","unstructured":"Feng Y, Yang Y, Zhao X, Fan Y, Zhou L, Rong J, et al. Circular RNA circ0005276 promotes the proliferation and migration of prostate cancer cells by interacting with FUS to transcriptionally activate XIAP. Cell Death Dis. 2019;10(11):792.","journal-title":"Cell Death Dis"},{"issue":"1","key":"378_CR31","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1038\/s41467-019-12049-0","volume":"10","author":"SB Zhang","year":"2019","unstructured":"Zhang SB, Lin SY, Liu M, Liu CC, Ding HH, Sun Y, et al. CircAnks1a in the spinal cord regulates hypersensitivity in a rodent model of neuropathic pain. Nat Commun. 2019;10(1):4119.","journal-title":"Nat Commun"},{"issue":"1","key":"378_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-019-1046-7","volume":"18","author":"L Wang","year":"2019","unstructured":"Wang L, Long H, Zheng Q, Bo X, Xiao X, Li B. Circular RNA circRHOT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression. Mol Cancer. 2019;18(1):119.","journal-title":"Mol Cancer"},{"key":"378_CR33","doi-asserted-by":"crossref","unstructured":"Guarnerio J, Zhang Y, Cheloni G, Panella R, Mae Katon J, Simpson M, et al. Intragenic antagonistic roles of protein and circRNA in tumorigenesis. Cell Res 2019; 29(8): 628\u201340.","DOI":"10.1038\/s41422-019-0192-1"},{"issue":"10088","key":"378_CR34","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492\u2013502.","journal-title":"Lancet"},{"issue":"7","key":"378_CR35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940\u201352.","journal-title":"Lancet Oncol"},{"issue":"4","key":"378_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380.","journal-title":"Lancet Oncol"},{"issue":"8","key":"378_CR37","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599\u2013611.","journal-title":"Nat Med"},{"issue":"3","key":"378_CR38","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell. 2020;37(3):324-39.e8.","journal-title":"Cancer Cell"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00378-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00378-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00378-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T08:10:52Z","timestamp":1675671052000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00378-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["378"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00378-2","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University and the Ethics Committee of the First Affiliated Hospital of Wannan Medical College. Informed consent was obtained from all participants. Animal research was conducted in compliance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines and approved by the Institutional Animal Care and Use Committee of Nanjing Medical University (No. 10791) and the Animal Welfare and Ethical Committee of Wannan Medical College (No. LLSC-2020-090).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}